Use of human skin substitutes expressing exogenous IL-12 to treat a wound bed
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Feb 27, 2024
Grant Date -
Jan 31, 2019
app pub date -
Oct 2, 2018
filing date -
May 21, 2009
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates generally to compositions for treating patients that have skin cancer or have recently had skin cancers removed. More specifically, the present invention provides human skin substitutes engineered to express exogenous IL-12 and compositions and methods for making human skin substitutes engineered to express exogenous IL-12. In addition, the present invention provides methods for treatment of sites on a patient where skin cancers have been removed with human skin substitutes engineered to express exogenous IL-12.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully